ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
New and emergent preparations for male hypogonadism treatment
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 269748" data-attributes="member: 13851"><p><strong><u>Figure 1. Mean hematocrit (HTC) increase</u> (a) or risk for developing erythrocytosis (b) after testosterone replacement therapy versus placebo according to the data derived from available meta-analysis.</strong></p><p><strong>[ATTACH=full]39184[/ATTACH]</strong></p><p><strong>[ATTACH=full]39185[/ATTACH]</strong></p><p><strong></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong>3.2. Secondary erythrocytosis</strong></p><p></p><p><em><strong>*</strong>The Endocrine Society [3] and the European Academy ofAndrology [11] guidelines suggest considering not starting TRT or using lower dosages in subjects with a <strong>hematocrit >50% [3], or > 52% [11], at baseline, particularly in those patients at high CV risk [11].</strong> Nevertheless, it is important to recognize that all the meta-analyses published so far indicate that <strong>TRT increases mean hematocrit by up to 5% and the risk of erythrocytosis by up to 7-fold [22,46,47] (see also Figure 1). However, the rise could be even higher [48] especially in older men [40,49] or in those with associated morbidities such as sleep apnea or chronic obstructive pulmonary diseases [42].</strong></em></p></blockquote><p></p>
[QUOTE="madman, post: 269748, member: 13851"] [B][U]Figure 1. Mean hematocrit (HTC) increase[/U] (a) or risk for developing erythrocytosis (b) after testosterone replacement therapy versus placebo according to the data derived from available meta-analysis. [ATTACH type="full" alt="Screenshot (30698).png"]39184[/ATTACH] [ATTACH type="full" alt="Screenshot (30699).png"]39185[/ATTACH] 3.2. Secondary erythrocytosis[/B] [I][B]*[/B]The Endocrine Society [3] and the European Academy ofAndrology [11] guidelines suggest considering not starting TRT or using lower dosages in subjects with a [B]hematocrit >50% [3], or > 52% [11], at baseline, particularly in those patients at high CV risk [11].[/B] Nevertheless, it is important to recognize that all the meta-analyses published so far indicate that [B]TRT increases mean hematocrit by up to 5% and the risk of erythrocytosis by up to 7-fold [22,46,47] (see also Figure 1). However, the rise could be even higher [48] especially in older men [40,49] or in those with associated morbidities such as sleep apnea or chronic obstructive pulmonary diseases [42].[/B][/I] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
New and emergent preparations for male hypogonadism treatment
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top